Literature DB >> 10080666

Measurement of the cost of screening for cervical cancer in the district of Florence, Italy.

M Zappa1, S Cecchini, S Ciatto, A Iossa, P Falini, M Mancini, E Paci.   

Abstract

AIMS AND
BACKGROUND: To estimate the cost per woman examined and per CIN II or more severe lesion detected in a population-based cytologic screening program for cervical cancer prevention. An organized cytologic screening program has been ongoing in the Florence District since 1973, and a call-recall system using mail invitation has been ongoing since 1980. Smear reading and assessment of screening positives is centralized at the screening unit. METHODS AND STUDY
DESIGN: All relevant resources (costs) consumed by the program were listed and measured. The unit cost per examined woman and per each CIN II or more severe lesion detected was estimated for each screening phase (recruitment, screening, assessment).
RESULTS: The cost per examined woman was $24.60, whereas that per CIN II or more severe lesion detected was $13,600. Staff accounted for 80% of total amount.
CONCLUSIONS: Although the cost for a single procedure is low, the cost per detected lesion is quite remarkable due to the low detection rate in a population screened for a long time. Different approaches and longer interval screening tests are discussed.

Entities:  

Mesh:

Year:  1998        PMID: 10080666     DOI: 10.1177/030089169808400603

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  2 in total

1.  Cost profiles of colorectal cancer patients in Italy based on individual patterns of care.

Authors:  Silvia Francisci; Stefano Guzzinati; Maura Mezzetti; Emanuele Crocetti; Francesco Giusti; Guido Miccinesi; Eugenio Paci; Catia Angiolini; Anna Gigli
Journal:  BMC Cancer       Date:  2013-07-05       Impact factor: 4.430

2.  Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.

Authors:  Paolo Giorgi Rossi; Alessandro Ricciardi; Catherine Cohet; Fabio Palazzo; Giacomo Furnari; Sabrina Valle; Nathalie Largeron; Antonio Federici
Journal:  BMC Public Health       Date:  2009-02-25       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.